These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3464282)

  • 1. Gemfibrozil treatment and the relationship between HDL cholesterol and apoE distribution in cholesterol-fed rats.
    Krause BR; Newton RS
    Atherosclerosis; 1986 Sep; 61(3):245-8. PubMed ID: 3464282
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical results with gemfibrozil.
    Pickering JE
    Am J Cardiol; 1983 Aug; 52(4):39B-40B. PubMed ID: 6351579
    [No Abstract]   [Full Text] [Related]  

  • 3. Gemfibrozil in the treatment of dyslipidaemia. A 5-year follow-up study.
    Manninen V; Mälkönen M; Eisalo A; Virtamo J; Tuomilehto J; Kuusisto P
    Acta Med Scand Suppl; 1982; 668():82-7. PubMed ID: 6762809
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
    Kesäniemi YA; Grundy SM
    JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
    Nye ER; Sutherland WH; Temple Wa
    N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein changes associated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats.
    Krause BR; Newton RS
    J Lipid Res; 1985 Aug; 26(8):940-9. PubMed ID: 3862732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
    Krause BR; Newton RS
    Atherosclerosis; 1986 Jan; 59(1):95-8. PubMed ID: 3081014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutritional & pharmacologic management of hyperlipoproteinemia.
    Pickering JE
    Angiology; 1982 Sep; 33(9):577-80. PubMed ID: 6957154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term use of gemfibrozil (Lopid) in the treatment of dyslipidemia.
    Lewis JE
    Angiology; 1982 Sep; 33(9):603-12. PubMed ID: 6957156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins.
    Vega GL; Grundy SM
    JAMA; 1985 Apr; 253(16):2398-403. PubMed ID: 3856692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
    N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.
    Sirtori CR; Franceschini G; Gianfranceschi G; Sirtori M; Montanari G; Tremoli E; Maderna P; Colli S; Zoppi F
    J Lab Clin Med; 1987 Sep; 110(3):279-86. PubMed ID: 3475394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from the Helsinki Heart Study. Fibric acid therapy for dyslipidemia.
    Grundy SM
    Postgrad Med; 1988 Jul; 84(1):217-8, 223-31. PubMed ID: 3164473
    [No Abstract]   [Full Text] [Related]  

  • 14. Change in composition of high density lipoprotein during gemfibrozil therapy.
    Sorisky A; Ooi TC; Simo IE; Meuffels M; Hindmarsh JT; Nair R
    Atherosclerosis; 1987 Oct; 67(2-3):181-9. PubMed ID: 3118893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cholesterol feeding on apo B and apo E concentrations and distributions in euthyroid and hypothyroid rats.
    DeLamatre JG; Roheim PS
    J Lipid Res; 1981 Feb; 22(2):297-306. PubMed ID: 7240959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of type III hyperlipoproteinemia with four different treatment regimens.
    Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB
    Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical results with gemfibrozil and background to the Helsinki Heart Study.
    Manninen V
    Am J Cardiol; 1983 Aug; 52(4):35B-38B. PubMed ID: 6351578
    [No Abstract]   [Full Text] [Related]  

  • 18. Gemfibrozil, lipids, and coronary risk.
    Rifkind BM
    N Engl J Med; 1987 Nov; 317(20):1279-81. PubMed ID: 3313042
    [No Abstract]   [Full Text] [Related]  

  • 19. A pilot study of the effect of Gemfibrozil on some haematological parameters.
    O'Brien JR; Etherington MD; Shuttleworth RD; Adams CM; Middleton JE; Goodland FC
    Thromb Res; 1982 May; 26(4):275-9. PubMed ID: 6955993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action of gemfibrozil on lipoprotein metabolism.
    Saku K; Gartside PS; Hynd BA; Kashyap ML
    J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.